Bio-techne Corp. has agreed to spend up to $325 million on an acquisition that represents the company's entry into the genomics market. Bio-techne said it will pay $250 million in cash for Advanced Cell Diagnostics (ACD) plus another $75 million tied to the achievement of certain milestones.

PARIS – It is hardly a thriller, but there are 700 pages to add to your summer reading that will give you chills sitting on the beach if your company is currently selling medical devices in the European Union, or if it plans to do so anytime soon.